Interactions of platelet factor 4 with the vessel wall

Seminars in Thrombosis and Hemostasis

Volumn 30, Issue 3, 2004, Pages 351-358

  Sachais, Bruce S ^b   Higazi, Abd Al Roof ^b   Cines, Douglas B ^b   Poncz, Mortimer ^a,b   Kowalska, M Anna ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Angiogenesis; Atherosclerosis; Chemokine; Heparin; PF4; Platelet factor 4; Thrombosis

Indexed keywords

CARBOHYDRATE BINDING PROTEIN; CHEMOKINE RECEPTOR CXCR3; FIBROBLAST GROWTH FACTOR 2; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; THROMBOCYTE FACTOR 4; VASCULOTROPIN;

ANGIOGENESIS; ATHEROGENESIS; ATHEROSCLEROSIS; BINDING AFFINITY; BLOOD VESSEL INJURY; BLOOD VESSEL WALL; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; THROMBOCYTE ACTIVATION; THROMBOGENESIS; THROMBOSIS;

ANIMALS; BLOOD PLATELETS; BLOOD VESSELS; CHEMOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; GLYCOSAMINOGLYCANS; HEPARITIN SULFATE; HUMANS; INFLAMMATION; MICE; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; PLATELET ACTIVATION; PLATELET FACTOR 4; PROTEIN BINDING; PROTEIN ISOFORMS; RECEPTORS, CHEMOKINE; THROMBOSIS;

EID: 3843100374     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-831048     Document Type: Review

References (57)

1. Stringer SE, Gallagher JT. Specific binding of the chemokine platelet factor 4 to heparan sulfate. J Biol Chem 1997;272: 20508-20514
2. Handin RI, Cohen HJ. Purification and binding properties of human platelet factor four. J Biol Chem 1976;251:4273-4282
3. Luster AD. Chemokines - chemotactic cytokines that mediate inflammation. N Engl J Med 1998;338:436-445
4. Fukami MH, Holmsen H, Kowalska MA, Niewiarowski S. Platelet secretion. In: Colman RW ea, ed. Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Philadelphia: Lippincott Williams & Wilkins; 2001:561-573
5. Zhang X, Chen L, Bancroft DP, Lai CK, Maione TE. Crystal structure of recombinant human platelet factor 4. Biochemistry 1994;33:8361-8366
6. Stuckey JA, St. Charles R, Edwards BF. A model of the platelet factor 4 complex with heparin. Proteins 1992;14:277-287
7. Lasagni L, Francalanci M, Annunziato F, et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 2003;197:1537-1549
8. Niewiarowski S. Report of the working party on platelets. Platelet factor 4 (PF4), platelet protein with heparin neutralizing activity. Thromb Haemost 1976;36:273-276
9. Gewirtz AM, Calabretta B, Rucinski B, Niewiarowski S, Xu WY. Inhibition of human megakaryocytopoiesis in vitro by platelet factor 4 (PF4) and a synthetic COOH-terminal PF4 peptide. J Clin Invest 1989;83:1477-1486
10. Zuker M, Katz I. Platelet factor 4: production, structure, and physiologic and immunologic action. Proc Soc Exp Biol Med 1991;198:693-702
11. Sharpe RJ, Byers HR, Scott CF, Bauer SI, Maione TE. Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4. J Natl Cancer Inst 1990;82:848-853
12. Maione TE, Gray GS, Petro J, et al. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990;247:77-79
13. Pitsilos S, Hunt JL, Mohler ER, et al. Platelet factor 4 localization in carotid atherosclerotic plaques: correlation with clinical parameters. Thromb Haemost 2003;90:1112-1120
14. Nassar T, Sachais BS, Akkawi S, et al. Platelet factor 4 enhances the binding of oxidized low-density lipoprotein to vascular wall cells. J Biol Chem 2003;278:6187-6193
15. Sachais BS, Kuo A, Nassar T, et al. Platelet factor 4 binds to low-density lipoprotein receptors and disrupts the endocytic itinerary, resulting in retention of low-density lipoprotein on the cell surface. Blood 2002;99:3613-3622
16. Lane DA, Denton J, Flynn AM, Thunberg L, Lindahl U. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J 1984;218:725-732
17. Dumenco LL, Everson B, Culp LA, Ratnoff OD. Inhibition of the activation of Hageman factor (factor XII) by platelet factor 4. J Lab Clin Med 1988;112:394-400
18. Mosnier L, Bouma BN, Griffin JH. Platelet Factor 4 upregulates protein C activation relative to TAFI activation. In: XIX Congress of The International Society on Thrombosis and Haemostasis. Birmingham, UK; 2003:OC376
19. Slungaard A, Key NN. Platelet factor 4 stimulates thrombomodulin protein C-activating cofactor activity. A structure-function analysis. J Biol Chem 1994;269:25549-25556
20. Dudek AZ, Pennell CA, Decker TD, Young TA, Key NS, Slungaard S. Platelet factor 4 binds to glycanated forms of thrombomodulin and to protein C. A potential mechanism for enhancing generation of activated protein C. J Biol Chem 1997;272:31785-31792
21. Slungaard A, Fernandez JA, Griffin JH, et al. Platelet factor 4 enhances generation of activated protein C in vitro and in vivo. Blood 2003;102:146-151
22. Esmon C. Are platelets anticoagulants? [editorial comment]. Blood 2003;102:3
23. Zhang C, Thornton MA, Kowalska MA, et al. Localization of distal regulatory domains in the megakaryocyte-specific platelet basic protein/platelet factor 4 gene locus. Blood 2001; 98:610-617
24. Eslin DE, Zhang C, Samuels KJ, et al. Transgenic mice studies demonstrate a role for platelet factor 4 in thrombosis: dissociation between anticoagulant and antithrombotic effect of heparin. Blood 2004. In press
25. Gewirtz AM, Zhang J, Ratajczak J, et al. Chemokine regulation of human megakaryocytopoiesis. Blood 1995;86:2559-2567
26. Kolber DL, Knisely TL, Maione TE. Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4. J Natl Cancer Inst 1995;87:304-309
27. Tanaka T, Manome Y, Wen P, Kufe DW, Fine HA. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat Med 1997;3:437-442
28. Maione TE, Gray GS, Hunt AJ, Sharpe RJ. Inhibition of tumor growth in mice by an analogue of platelet factor 4 that lacks affinity for heparin and retains potent angiostatic activity. Cancer Res 1991;51:2077-2083
29. Jouan V, Canron X, Alemany M, et al. Inhibition of in vitro angiogenesis by platelet factor-4-derived peptides and mechanism of action. Blood 1999;94:984-993
30. Brown KJ, Parish CR. Histidine-rich glycoprotein and platelet factor 4 mask heparan sulfate proteoglycans recognized by acidic and basic fibroblast growth factor. Biochemistry 1994;33:13918-13927
31. Perollet C, Han ZC, Savona C, Caen JP, Bikfalvi A. Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization. Blood 1998;91:3289-3299
32. Sulpice E, Bryckaert M, Lacour J, Contreres JO, Tobelem G. Platelet factor 4 inhibits FGF2-induced endothelial cell proliferation via the extracellular signal-regulated kinase pathway but not by the phosphatidylinositol 3-kinase pathway. Blood 2002;100:3087-3094
33. Gengrinovitch S, Greenberg SM, Cohen T, et al. Platelet factor-4 inhibits the mitogenic activity of VEGF121 and VEGF165 using several concurrent mechanisms. J Biol Chem 1995;270:15059-15065
34. LeBreton H, Topol E, Plow EF. Evidence for a pivotal role of platelets in vascular reocclusion and restenosis. Cardiovasc Res 1996;31:235-236
35. Harker LA. Inhibitors of platelet function in the prevention of arterial thrombosis. Ser Haematol 1975;8:105-124
36. Sinzinger H, Kaliman J, Fitscha P, O'Grady J. Diminished platelet residence time on active human atherosclerotic lesions in-vivo - evidence for an optimal dose of aspirin? Prostaglandins Leukot Essent Fatty Acids 1988;34:89-93
37. Sachais BS. Platelet-endothelial interactions in atherosclerosis. Curr Atheroscler Rep 2001;3:412-416
38. O'Brien JR, Etherington MD, Pashley M. Intra-platelet platelet factor 4 (IP.PF4) and the heparin-mobilisable pool of PF4 in health and atherosclerosis. Thromb Haemost 1984;51: 354-357
39. Sevitt S. Platelets and foam cells in the evolution of atherosclerosis. Histological and immunohistological studies of human lesions. Atherosclerosis 1986;61:107-115
40. Chesterman CN, Berndt MC. Platelet and vessel wall interaction and the genesis of atherosclerosis. Clin Haematol 1986; 15:323-353
41. Davies MJ. The contribution of thrombosis to the clinical expression of coronary atherosclerosis. Thromb Res 1996;82: 1-32
42. Holvoet P, Collen D. Thrombosis and atherosclerosis. Curr Opin Lipidol 1997;8:320-328
43. Hawiger J. Mechanisms involved in platelet vessel wall interaction. Thromb Haemost 1995;74:369-372
44. Woolf N, Carstairs KC. Infiltration and thrombosis in atherogenesis. A study using immunofluorescent techniques. Am J Pathol 1967;51:373-386
45. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-809
46. Fuhrman B, Brook GJ, Aviram M. Activated platelets secrete a protein-like factor that stimulates oxidized-LDL receptor activity in macrophages. J Lipid Res 1991;32:1113-1123
47. Kruth HS. Platelet-mediated cholesterol accumulation in cultured aortic smooth muscle cells. Science 1985;227:1243-1245
48. Gawaz M, Neumann FJ, Dickfeld T, et al. Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells. Circulation 1998;98:1164-1171
49. Lindemann S, Tolley ND, Dixon DA, et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1 {beta} synthesis. J Cell Biol 2001;154:485-490
50. Johnson RC, Chapman SM, Dong ZM, et al. Absence of P-selectin delays fatty streak formation in mice. J Clin Invest 1997;99:1037-1043
51. Manka D, Collins RG, Ley K, Beaudet AL, Sarembock IJ. Absence of p-selectin, but not intercellular adhesion molecule-1, attenuates neointimal growth after arterial injury in apolipoprotein e-deficient mice. Circulation 2001;103:1000-1005
52. Collins RG, Velji R, Guevara NV, Hicks MJ, Chan L, Beaudet AL. P-Selectin or intercellular adhesion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein E-deficient mice. J Exp Med 2000; 191:189-194
53. Burger PC, Wagner DD. Platelet P-selectin facilitates atherosclerotic lesion development. Blood 2003;101:2661-2666
54. Massberg S, Brand K, Gruner S, et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002;196:887-896
55. Huo Y, Schober A, Forlow SB, et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003;9:61-67
56. Scheuerer B, Ernst M, Durrbaum-Landmann I, et al. The CXC-chemokine platelet factor 4 promotes monocyte survival and induces monocyte differentiation into macrophages. Blood 2000;95:1158-1166
57. Deuel TF, Senior RM, Chang D, Griffin GL, Heinrikson RL, Kaiser ET. Platelet factor 4 is chemotactic for neutrophils and monocytes. Proc Natl Acad Sci USA 1981;78:4584-4587